



## SHORT COMMUNICATION

## Mental disorders and drug/alcohol use in patients commencing extensively drug-resistant tuberculosis treatment

J. Scuffell,<sup>1</sup> D. Boccia,<sup>2</sup> F. Garcia Velarde,<sup>3</sup> S. R. Leon,<sup>3</sup> G. Raviola,<sup>4</sup> L. Lecca,<sup>3,4</sup> J. T. Galea<sup>3,4</sup><http://dx.doi.org/10.5588/pha.17.0044>

Mental disorders and alcohol/drug use worsen treatment outcomes for multidrug-resistant tuberculosis (TB), but data are lacking for extensively drug-resistant (XDR) TB. We investigated the association of baseline mental disorders and alcohol/drug use on XDR-TB treatment outcomes in a retrospective study of 53 XDR-TB Peruvian patients during 2010–2012. Logistic regression estimated the odds ratios for unfavourable XDR-TB treatment outcomes. Overall treatment success was 25%. Mental disorders and drug/alcohol use were found in respectively 22.4% and 20.4% of patients; neither were associated with unfavourable treatment outcomes. Future research should explore the relationship between mental health and drug/alcohol use in XDR-TB treatment outcomes.

Adherence to antimicrobial regimens is critical for optimal tuberculosis (TB) treatment. Comorbid mental disorders, including depression, anxiety, psychosis and drug/alcohol use disorders—present in up to 70% of TB patients<sup>1</sup>—are associated with poorer outcomes.<sup>2</sup> While some patients begin anti-tuberculosis treatment with pre-existing mental disorders, onset sometimes occurs due to added bio-psychosocial stressors during TB treatment, psychiatric side-effects of anti-tuberculosis drugs or drug interactions between antimicrobial and antipsychotic medications.<sup>1,3</sup> Particularly for patients with multi-drug resistant (MDR) TB, where treatment can last for years, addressing comorbid mental disorders such as depression increases cure rates and patient wellbeing.<sup>4</sup> A study from Peru was among the first to demonstrate the benefit of psychosocial support for MDR-TB patients with mental disorders, reporting a TB treatment non-completion rate of 3%.<sup>5</sup> Nonetheless, integrated TB and mental health services are not the global norm.<sup>3</sup> Moreover, only scant data exist on the prevalence of mental health comorbidities among MDR-TB patients, and we are unaware of any published data for extensively drug-resistant (XDR) TB, which requires longer, more toxic treatment regimens.

Peru, designated by the World Health Organization (WHO) as a high MDR-TB burden country, has an annual MDR-TB incidence rate of 10 per 10000 population.<sup>6</sup> This pilot study investigated the baseline prevalence of comorbid mental disorders and drug/alcohol use and their association with outcomes among a small sample of Peruvian XDR-TB patients.

## ASPECT OF INTEREST

## Methods

We conducted a retrospective case series analysing patients commencing their first XDR-TB treatment episode in Peru during 2010–2012. In accordance with Peru's National TB Programme (NTP) recommendations, XDR-TB patients receive a baseline clinical assessment from a psychologist or psychiatrist to screen for mental health conditions using the International Classification of Diseases 10<sup>th</sup> revision (ICD-10). Demographic and clinical data were abstracted from medical charts in the NTP's central archive onto paper forms during June–July 2015. The data were then single-entered and cleaned electronically using EpiData v3.1 (EpiData Association, Odense, Denmark), Excel 2011 (Microsoft Corp, Redmond, USA) and q (Ben-Atia Harel, Israel).

The prevalence of mental disorders—depression, anxiety, mixed anxiety-depressive disorder and psychosis—and alcohol and drug use was calculated. Using the Peruvian NTP definition for XDR-TB treatment outcomes (Table 1), we estimated the crude odds ratios (OR) for unfavourable (failure, loss to follow-up, death) outcomes for mental disorders and current drug/alcohol use using exact logistic regression using Stata 13.0 (StataCorp, College Station, TX, USA).

The study was approved by the Human Ethics Research Committees at the Universidad Peruana Cayetano Heredia (Lima, Peru) and London School of Hygiene & Tropical Medicine (London, UK).

## RESULTS

We abstracted treatment data for 53 XDR-TB patients who were mostly males aged 19–66 years living in metropolitan Lima/Callao. One patient was a secondary XDR-TB case, while the remainder had a median of 2.35 years of previous anti-tuberculosis treatment (interquartile range [IQR] 9.6 months–3.75 years). Of the 53 patients, 49 had documented psychiatric evaluations, of whom 11/49 were diagnosed with a mental disorder: five with depression, three with anxiety, two with mixed anxiety-depressive disorder and one with psychosis. Overall treatment outcomes were: 12/49 favourable (seven cured, five completed) and 37/49 unfavourable (11 lost to follow-up, 11 failures and 15 deaths). Among those diagnosed with mental disorders, 9/11 had an unfavourable treatment outcome.

## AFFILIATIONS

- 1 Epsom and St Helier University Hospitals NHS Trust, London, UK
- 2 Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK
- 3 Socios En Salud, Lima, Peru
- 4 Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA

## CORRESPONDENCE

Jerome T Galea  
Department of Global Health and Social Medicine  
Harvard Medical School  
641 Huntington Ave  
Boston, MA 02115, USA  
e-mail: [jerome\\_galea@hms.harvard.edu](mailto:jerome_galea@hms.harvard.edu)

## KEY WORDS

depression; anxiety; psychosis; alcohol; XDR-TB

Received 30 May 2017  
Accepted 24 July 2017

PHA2017;7(3):237–239  
© 2017 Scuffell et al.

**TABLE 1** Definitions of XDR-TB treatment outcomes, Peru National Tuberculosis Programme

Outcome	Definition
Cure	Completion of at least 24 months of XDR-TB treatment, with 10 negative cultures in the final 12 months of treatment
Completion	Completion of treatment on the advice of a physician, without other criteria to categorize the treatment as cure
Loss to follow-up	Interruption of treatment for $\geq 30$ days
Failure	Failure to achieve sputum conversion by the 6 <sup>th</sup> month of treatment (two consecutive cultures at least 30 days apart), or bacteriological reversion (two consecutive positive cultures at least 30 days apart) or amplification of resistance
Death	Death from any cause during XDR-TB treatment

XDR-TB = extensively drug-resistant tuberculosis.

Three of the four patients without psychiatric assessments had unfavourable outcomes (Table 2).

Regarding alcohol use, 8/49 patients were consuming alcohol at baseline, of whom two were diagnosed with alcoholism. A further 11/49 had a history of alco-

hol consumption. Six patients currently used drugs; five more had a history of drug use. Nearly half (22/49) had a current or prior history of alcohol/drug use; these patients tended to have unfavourable outcomes.

There was no statistical evidence that a diagnosis of mental disorder (OR 1.59, 95% confidence interval [CI] 0.26–7.6,  $P = 0.70$ ) or current alcohol/drug use (OR 0.71, 95%CI 0.12–5.09,  $P = 0.69$ ) were associated with increased odds of worse XDR-TB treatment outcomes.

## DISCUSSION

To our knowledge, this retrospective series is the first to report on XDR-TB psychiatric comorbidity in Peru or elsewhere. The point prevalences of baseline depression and anxiety observed in this cohort of XDR-TB patients were greater than for the adult population of Lima/Callao (10.2% vs. 2.8% and 6.1% vs. 1.9%, respectively), while rates of psychosis and alcohol/drug use were comparable to the general population.<sup>7</sup> Compared to the first 75 MDR-TB patients in Peru to receive individualised therapy (1996–1999), depression was less prevalent in the present study (10.2% vs. 52.2%), but the prevalence of anxiety was similar (6.1% vs. 8.7%).<sup>8</sup> However, our results for all psychiatric conditions are comparable to a larger MDR-TB cohort in Peru (22.4% vs. 18.9%).<sup>2</sup> Nonetheless, we

## ACKNOWLEDGEMENTS

The authors thank the Tuberculosis Prevention and Control Directorate of the Peruvian Ministry of Health (Lima, Peru) for allowing access to patient health records. We also thank A Sweetland for her review of the manuscript.

JTG received support from the Abundance Foundation Fellowship in Global Mental Health Implementation Science.

Conflicts of interest: none reported.

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**TABLE 2** Prevalence of psychiatric conditions at baseline among 49 patients commencing XDR-TB treatment in Peru, 2010–2012

	(N = 49) n	Prevalence % (95%CI)	Unfavourable outcomes n (%)	Unfavourable outcomes Crude OR (95%CI)	P value*
Sex					
Female	17	34.7 (22.4–49.4)	14 (82)		
Male	32	65.3 (50.6–77.6)	23 (72)		
Age at initiation of XDR-TB treatment, years					
19–25	12	24.5 (14.2–38.9)	10 (83)		
26–40	21	42.9 (29.4–57.4)	15 (71)		
41–66	16	32.7 (20.7–47.4)	12 (75)		
Mental disorder, alcohol or drug use					
Current	17	34.7 (22.4–49.4)	13 (76)		
Not current	32	65.3 (50.6–77.6)	24 (75)		
Mental disorder	11	22.4 (12.6–36.7)	9 (82)	1.59 (0.26–17.6)	0.71
Depression	5	10.2 (4.2–22.9)	4 (80)		
Anxiety	3	6.1 (1.9–18.0)	3 (100)		
Mixed anxiety-depressive disorder	2	4.1 (1.0–15.6)	2 (100)		
Psychosis	1	2.0 (0.2–14.0)	0		
No mental disorder	38	77.6 (63.3–87.4)	28 (74)		
Alcohol and drug use	22	44.9 (31.3–59.4)	15 (68)		
Current					
All	10	20.4 (11.1–34.5)	7 (70)	0.71 (0.12–5.09)	0.69
Alcohol	8	16.3 (8.2–30.0)	6 (75)		
Alcoholism	2	4.1 (1.0–15.6)	2 (100)		
Drugs <sup>†</sup>	6	12.2 (5.4–25.3)	4 (67)		
Past					
All	13	26.5 (15.8–41.1)	8 (62)		
Alcohol	11	22.4 (12.6–36.7)	6 (55)		
Drugs <sup>†</sup>	5	10.2 (4.2–22.9)	3 (60)		
No current alcohol or drug use	39	79.6 (65.5–88.9)	30 (77)		

\* Derived from conditional score tests.

<sup>†</sup> Marijuana, cocaine/cocaine precursor.

XDR-TB = extensively drug-resistant tuberculosis; CI = confidence interval; OR = odds ratio.

found no association of psychiatric conditions or drug/alcohol use with unfavourable XDR-TB outcomes.

Prospective studies and qualitative inquiry would shed further light on these unexpected findings. It may be that patients with pre-existing (prior to XDR-TB treatment) mental disorders were less likely to present for care, or had died before they could, and were therefore underrepresented in our sample. Alternatively, patients may have been too gravely ill to be evaluated with appropriate instruments, thereby underestimating the true prevalence of psychiatric disorders. Patients who were not using alcohol/drugs at baseline may have restarted once treatment improved their TB symptomatology. As it is unlikely that psychiatric disorders are protective factors during XDR-TB treatment, NTPs should assume that mental health interventions would increase patient wellbeing and reduce loss to follow-up. Initiatives such as the WHO End TB strategy<sup>9</sup> and Zero TB,<sup>10</sup> which include mental health support as core components, offer promise; however, more data are needed on specific comorbid mental disorders with XDR-TB to develop the most successful interventions.

Due to the small sample size and missing data, such as patients' socio-economic status and whether diagnoses were made by psychiatrists or psychologists, key confounders cannot be ruled out. As the mental health evaluations were performed at treatment initiation, we could not assess the incidence of mental disorders.

## CONCLUSION

Baseline psychiatric disorders and drug/alcohol use were not associated with poor XDR-TB outcomes; however, overall treatment success was low. Appropriately powered cohort studies are needed

Les troubles mentaux et la consommation d'alcool/de drogue entravent le résultat du traitement de la tuberculose multirésistante (TB-MDR), mais on manque de données pour la TB ultrarésistante (TB-XDR). Nous avons examiné l'association de troubles mentaux préexistants et de consommation d'alcool/de drogue sur le résultat du traitement de la TB-XDR dans une étude rétrospective de 53 patients péruviens atteints de TB-XDR en 2010–2012. Une régression logistique a estimé les odds ratios de résultat défavorable du

Los trastornos mentales y el consumo de alcohol y de drogas agravan los desenlaces terapéuticos de la tuberculosis multidrogorresistente (TB-MDR), pero no existen datos en cuanto a la TB extremadamente resistente (TB-XDR). En un estudio retrospectivo en 53 pacientes peruanos que padecieron TB-XDR del 2010 al 2012, se investigó la asociación de la presencia inicial de trastornos mentales y consumo de alcohol o drogas con los desenlaces del tratamiento de la TB-XDR. Mediante un modelo de regresión logística se calcularon los cocientes

to better understand mental health issues affecting XDR-TB patients throughout treatment and develop interventions that improve patients' survival and quality of life.

## References

- 1 Doherty A M, Kelly J, McDonald C, O'Dwyer A M, Keane J, Cooney J. A review of the interplay between tuberculosis and mental health. *Gen Hosp Psychiatry* 2013; 35: 398–406.
- 2 Franke M F, Appleton S C, Bayona J, et al. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. *Clin Infect Dis* 2008; 46:1844–1851.
- 3 Walker I F, Baral S C, Wei X, et al. Multidrug-resistant tuberculosis treatment programmes insufficiently consider comorbid mental disorders. *Int J Tuberc Lung Dis* 2017; 21: 603–609.
- 4 Sweetland A, Oquendo M, Wickramaratne P, Weissman M, Wainberg M. Depression: a silent driver of the global tuberculosis epidemic. *World psychiatry* 2014; 13: 325–326.
- 5 Acha J, Sweetland A, Guerra D, Chalco K, Castillo H, Palacios E. Psychosocial support groups for patients with multidrug-resistant tuberculosis: five years of experience. *Glob Public Health* 2007; 2: 404–417.
- 6 World Health Organization. Global tuberculosis report, 2016. WHO/HTM/TB/2016.13. Geneva, Switzerland: WHO, 2016. <http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf?ua=1/> Accessed August, 2017.
- 7 Instituto Nacional de Salud Mental Honorio Delgado. Estudio epidemiológico de salud mental en Lima Metropolitana y Callao - replicación 2012. Lima, Peru: Instituto Nacional de Salud Mental, 2013. <http://www.insm.gov.pe/investigacion/archivos/estudios/2012%20ASM%20-EESM%20-LM.pdf> Accessed July 2017. [Spanish]
- 8 Vega P, Sweetland A, Acha J, et al. Psychiatric issues in the management of patients with multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis* 2004; 8: 749–759.
- 9 World Health Organization. The WHO End TB Strategy. WHO/HTM/TB/2015.19. Geneva, Switzerland: WHO, 2015. [http://www.who.int/tb/post2015\\_strategy/en/](http://www.who.int/tb/post2015_strategy/en/) Accessed August 2017.
- 10 Stop TB Partnership. The 'Zero TB Initiative' sparks new action to end TB. Geneva, Switzerland: Stop TB Partnership, 2016. [http://www.stoptb.org/news/stories/2016/ns16\\_034.asp](http://www.stoptb.org/news/stories/2016/ns16_034.asp) Accessed August 2017.

traitement de la TB-XDR. Le taux d'ensemble de succès du traitement a été de 25%. Des troubles mentaux et une consommation d'alcool/de drogue ont été constatés chez respectivement 22,4% et 20,4% des patients; aucun n'a été associé à un résultat défavorable du traitement. Des recherches ultérieures devraient explorer la relation entre santé mentale et consommation de drogue/alcool et leur impact sur le traitement de la TB-XDR.

de posibilidades de desenlaces terapéuticos desfavorables. La tasa global de éxito terapéutico fue de 25%. Se encontró que el 22,4% de los pacientes sufría trastornos mentales y el 20,4% consumía alcohol o drogas; ninguna de estas características se asoció con desenlaces desfavorables del tratamiento. Nuevas investigaciones tendrán que explorar la correlación que existe entre la salud mental y el consumo de alcohol o drogas y los desenlaces terapéuticos de la TB-XDR.